Logo do repositório
 
Publicação

Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients

2015Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRomão, Vasco C.
dc.contributor.authorSantos, Maria José
dc.contributor.authorPolido-Pereira, Joaquim
dc.contributor.authorDuarte, Cátia
dc.contributor.authorNero, Patrícia
dc.contributor.authorMiguel, Cláudia
dc.contributor.authorCosta, José António
dc.contributor.authorBernardes, Miguel
dc.contributor.authorPimentel-Santos, Fernando M.
dc.contributor.authorM. Pimentel-Santos, F.
dc.contributor.authorBarcelos, Filipe
dc.contributor.authorBarcelos, Filipe
dc.contributor.authorCosta, Maria Lúcia
dc.contributor.authorMelo Gomes, José António
dc.contributor.authorPereira Da Silva, José Alberto
dc.contributor.authorBranco, Jaime
dc.contributor.authorBranco, Jaime
dc.contributor.authorCanas da Silva, José
dc.contributor.authorPereira Da Silva, José António
dc.contributor.authorFonseca, João Eurico
dc.contributor.authorCanhão, Helena
dc.contributor.authorCanhão, Helena
dc.contributor.authorShi, Guixiu
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.pblHindawi
dc.date.accessioned2017-07-13T22:01:48Z
dc.date.available2017-07-13T22:01:48Z
dc.date.issued2015
dc.description.abstractObjectives. To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods. We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders. Results. Tocilizumab-treated patients (n = 95) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users (n = 429). Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6-21.6/3.2-12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2-6.5/1.3-5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5-8.7/1.1-5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4-12.0). However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8-4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8-4.5). Conclusions. Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response. Boolean remission and EULAR good/moderate response did not differ significantly between groups.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent13
dc.format.extent1659095
dc.identifier.doi10.1155/2015/279890
dc.identifier.issn2314-6133
dc.identifier.otherPURE: 2928022
dc.identifier.otherPURE UUID: b2b02066-a1c7-4101-8caf-43cfc02dfd1c
dc.identifier.otherScopus: 84929346565
dc.identifier.otherPubMed: 26000286
dc.identifier.otherWOS: 000354293300001
dc.identifier.otherORCID: /0000-0003-1894-4870/work/67178257
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=84929346565&partnerID=8YFLogxK
dc.identifier.urlhttps://www.scopus.com/pages/publications/84929346565
dc.language.isoeng
dc.peerreviewedyes
dc.subjectINTERLEUKIN-6 RECEPTOR INHIBITION
dc.subjectDRUG SURVIVAL
dc.subjectDOUBLE-BLIND
dc.subjectADALIMUMAB
dc.subjectREMISSION
dc.subjectEFFICACY
dc.subjectTRIAL
dc.subjectETANERCEPT
dc.subjectINFLIXIMAB
dc.subjectSAFETY
dc.subjectGeneral Immunology and Microbiology
dc.subjectGeneral Biochemistry,Genetics and Molecular Biology
dc.titleComparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patientsen
dc.title.subtitleData from the Rheumatic Diseases Portuguese Register, Reuma.pten
dc.typejournal article
degois.publication.firstPage
degois.publication.lastPage
degois.publication.titleBioMed Research International
degois.publication.volume2015
dspace.entity.typePublication
person.familyNamePimentel-Santos
person.familyNameBarcelos
person.familyNameBranco
person.familyNameCanhão
person.givenNameFernando
person.givenNameFilipe
person.givenNameJaime
person.givenNameHelena
person.identifier394707
person.identifier379800
person.identifier.ciencia-idCE12-F61E-3227
person.identifier.ciencia-idB612-E5C3-60DC
person.identifier.ciencia-id5A17-C6D9-DBC8
person.identifier.orcid0000-0002-2816-7705
person.identifier.orcid0000-0002-3764-0808
person.identifier.orcid0000-0001-7024-4375
person.identifier.orcid0000-0003-1894-4870
person.identifier.ridC-9611-2018
person.identifier.scopus-author-id35249227600
person.identifier.scopus-author-id8417815400
person.identifier.scopus-author-id6602393492
rcaap.rightsopenAccess
relation.isAuthorOfPublicationdc1c295c-5cad-49f3-9b79-26b1fd03de49
relation.isAuthorOfPublicationf74be637-6f68-4297-9620-e6ef2356afc9
relation.isAuthorOfPublication4caea9f3-40dd-4c95-98ec-0120509287c0
relation.isAuthorOfPublicationc87f58c0-b53d-4321-9bd7-39554e6001b5
relation.isAuthorOfPublication.latestForDiscoverydc1c295c-5cad-49f3-9b79-26b1fd03de49

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
279890.pdf
Tamanho:
1.58 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica